FBW7 upregulation enhances cisplatin cytotoxicity in nonsmall cell lung cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6321-6326

  Yu, Hao Gang ^a   Wei, Wei ^a   Xia, Li Hong ^a   Han, Wei Li ^a   Zhao, Peng ^a   Wu, Sheng Jun ^a   Li, Wei Dong ^a   Chen, Wei ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cisplatin; Drug resi; Epithelial mesenchymal transition; FBW7; NSCLC cells

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CISPLATIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; F-BOX PROTEINS; HUMANS; LUNG NEOPLASMS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 84892462247     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6321     Document Type: Article

References (41)

1. Akhoondi S, Sun D, von der Lehr N, et al (2007). FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res, 67, 9006-12.
2. Anzi S, Finkin S, Shaulian E (2008). Transcriptional repression of c-Jun's E3 ubiquitin ligases contributes to c-Jun induction by UV. Cell Signal, 20, 862-71.
3. Bonetti P, Davoli T, Sironi C, et al (2008). Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol, 182, 19-26.
4. Byers LA, Diao L, Wang J, et al (2013). An epithelialmesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res, 19, 279-90.
5. Calhoun ES, Jones JB, Ashfaq R, et al (2003). BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol, 163, 1255-60.
6. Cassia R, Moreno-Bueno G, Rodriguez-Perales S, et al (2003). Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol, 201, 589-95.
7. Cortot AB, Repellin CE, Shimamura T, et al (2013). Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res, 73, 834-43.
8. Fruh M (2011). The search for improved systemic therapy of non-small cell lung cancer--what are today's options. Lung Cancer, 72, 265-70.
9. Grim JE, Gustafson MP, Hirata RK, et al (2008). Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol, 181, 913-20.
10. Grunert S, Jechlinger M, Beug H (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol, 4, 657-65.
11. Hoshino H, Miyoshi N, Nagai K, et al (2009). Epithelialmesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem Biophys Res Commun, 390, 1061-5.
12. Inuzuka H, Fukushima H, Shaik S, et al (2011). Mcl-1 ubiquitination and destruction. Oncotarget, 2, 239-44.
13. Inuzuka H, Shaik S, Onoyama I, et al (2011). SCF (FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 471, 104-9.
14. Jemal A, Murray T, Samuels A, et al (2003). Cancer statistics, 2003. CA Cancer J Clin, 53, 5-26.
15. Kitagawa K, Hiramatsu Y, Uchida C, et al (2009). Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene, 28, 2393-405.
16. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al (2009). Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells, 27, 2059-68.
17. Kwak EL, Moberg KH, Wahrer DC, et al (2005). Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol, 98, 124-8.
18. Lee MS, Kim HP, Kim TY, Lee JW (2012). Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelialmesenchymal transition. Biochim Biophys Acta, 1823, 514-23.
19. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH (2011). Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One, 6, e16068.
20. Mao JH, Perez-Losada J, Wu D, et al (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature, 432, 775-9.
21. Melguizo C, Prados J, Luque R, et al (2013). Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance. Cancer Chemother Pharmacol, 71, 537-41.
22. Moreno-Bueno G, Peinado H, Molina P, et al (2009). The morphological and molecular features of the epithelial-tomesenchymal transition. Nat Protoc, 4, 1591-613.
23. Nash P, Tang X, Orlicky S, et al (2001). Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature, 414, 514-21.
24. Nateri AS, Riera-Sans L, Da Costa C, Behrens A (2004). The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science, 303, 1374-8.
25. Neel DS, Bivona TG (2013). Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res, 19, 3-5.
26. Nozawa N, Hashimoto S, Nakashima Y, et al (2006). Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract, 202, 639-50.
27. O'Neil J, Grim J, Strack P, et al (2007). FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med, 204, 1813-24.
28. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW (2008). FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res, 32, 1751-5.
29. Spruck CH, Strohmaier H, Sangfelt O, et al (2002). hCDC4 gene mutations in endometrial cancer. Cancer Res, 62, 4535-9.
30. Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2, 442-54.
31. Thiery JP (2003). Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol, 15, 740-6.
32. Thiery JP, Acloque H, Huang RY, Nieto MA (2009). Epithelialmesenchymal transitions in development and disease. Cell, 139, 871-90.
33. Thompson BJ, Buonamici S, Sulis ML, et al (2007). The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med, 204, 1825-35.
34. Thomson S, Buck E, Petti F, et al (2005). Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res, 65, 9455-62.
35. Wertz IE, Kusam S, Lam C, et al (2011). Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 471, 110-4.
36. Willmarth NE, Albertson DG, Ethier SP (2004). Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res, 6, R531-9.
37. Wozniak AJ, Gadgeel SM (2007). Adjuvant treatment of nonsmall- cell lung cancer: how do we improve the cure rates further. Oncology (Williston Park), 21, 163-71; discussion 71, 74, 79-82.
38. Yauch RL, Januario T, Eberhard DA, et al (2005). Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res, 11, 8686-98.
39. Zeisberg M, Neilson EG (2009). Biomarkers for epithelialmesenchymal transitions. J Clin Invest, 119, 1429-37.
40. Zhang W, Koepp DM (2006). Fbw7 isoform interaction contributes to cyclin E proteolysis. Mol Cancer Res, 4, 935-43.
41. Zhang Z, Lee JC, Lin L, et al (2012). Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet, 44, 852-60.